Vyndaqel (Tafamidis meglumine) Approval in the EU for treatment of TTR-FAP in adult November 2011 — patients with stage 1 symptomatic polyneuropathy

    Tofacitinib Application filed in the EU for treatment of moderate-to- — November 2011 severe active rheumatoid arthritis

    Prevenar 13 Adult Approval in the EU for prevention of invasive October 2011 — pneumococcal disease in adults 50 years of age and

older

    Sutent Application filed in Japan for treatment of pancreatic — October 2011 neuroendocrine tumor

    Lyrica Application filed in Japan for treatment of fibromyalgia — October 2011

    ELIQUIS (Apixaban)(a) Application filed in the EU for prevention of stroke in — October 2011 patients with atrial fibrillation

    Bosutinib Application filed in the EU for treatment of newly — August 2011 diagnosed chronic myelogenous leukemia

    Crizotinib Application filed in the EU for treatment of previously — August 2011 treated ALK-positive advanced non-small cell lung

cancer

    Axitinib Application filed in Japan for treatment of advanced — July 2011 renal cell carcinoma after failure of prior systemic

treatment

    ELIQUIS Approval in the EU for prevention of venous May 2011 — (Apixaban)(b) thromboembolism following elective hip or knee-

replacement surgery

    Axitinib Application filed in the EU for treatment of advanced — May 2011 renal cell carcinoma after failure of prior systemic

treatment

    Revatio Approval in the EU for pediatric PAH May 2011 —

    Crizotinib Application filed in Japan for treatment of ALK-positive — March 2011 advanced non-small cell lung cancer

    Xiapex Approval in the EU for treatment of Dupuytren’s February 2011 — contracture

    Sutent Approval in the EU for treatment of unresectable December 2010 — pancreatic neuroendocrine tumor

    Taliglucerase alfa Application filed in the EU for treatment of Gaucher — November 2010 disease

  * For applications in the EU, the dates set forth in this column are the dates on which the European Medicines Agency (EMA) validated our submissions.

(a) This indication for ELIQUIS (apixaban) is being developed in collaboration with BMS.

(b) This indication for ELIQUIS (apixaban) was developed and is being commercialized in collaboration with BMS.

In March 2011, we decided to withdraw our application in Japan for Toviaz for the treatment of overactive bladder due to required stability testing. We intend to resubmit the application in the first half of 2012.

In March 2010, we withdrew our application in Japan for Prevenar 13 for the prevention of invasive pneumococcal disease in infants and young children due to a request by the Pharmaceutical and Medical Devices Agency (PMDA) for an additional study of this indication in Japanese subjects. We are conducting the requested additional study and, if the results are positive, we plan to resubmit the application.

  Late-stage clinical trials for additional uses and dosage forms for in-line and in-registration products:

  PRODUCT INDICATION

  ELIQUIS (Apixaban) For the prevention and treatment of venous thromboembolism, which is being developed in collaboration with BMS

  Eraxis/Vfend Combination